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Abstract Objective: To investigate
efficacy and safety of enoxaparin for
catheter-related arterial thrombosis in
infants with congenital heart disease.
Design: Prospective observational
study. Setting: Pediatric Intensive
Care and Cardiology Unit at the Uni-
versity Children’s Hospital of Zurich.
Patients: A cohort of 32 infants aged
0–12 months treated with enoxa-
parin for catheter-related arterial
thrombosis from 2002 to 2005.
Measurements: Dose requirements
of enoxaparin, resolution of throm-
bosis by Doppler ultrasound, and
bleeding complications. Results:
Catheter-related arterial throm-
bosis was located in the iliac/femoral
arteries in 31 (97%) infants and
aorta in 1 infant, and was related
to indwelling catheters and cardiac
catheterization in 17 (53%) and 15
(47%) cases, respectively. New-
borns required increased doses of
enoxaparin to achieve therapeutic
anti-FXa levels (mean 1.62 mg/kg
per dose) compared with infants aged
2–12 months (mean 1.12 mg/kg per
dose; p = 0.0002). Complete resolu-
tion of arterial thrombosis occurred in
29 (91%) infants at a mean of 23 days
after initiation of enoxaparin therapy.
Partial or no resolution was observed
in 1 (3%) and 2 (6%) infants, respec-
tively, at a mean follow-up time of
4.3 months. Bleeding complications
occurred in 1 (3%) infant. Conclu-
sion: Enoxaparin is efficient and
safe for infants with congenital heart
disease and catheter-related arterial
thrombosis, possibly representing
a valid alternative to the currently rec-
ommended unfractionated heparin.
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Introduction
Catheter-related arterial thrombi are increasingly rec-
ognized serious complications of advances in intensive
care and cardiac catheterization techniques used for
the treatment of congenital heart disease (CHD) in in-
fants [1–3]. Untreated, catheter-related arterial thrombosis
possibly increases long-term morbidity including early
onset of occlusive peripheral arterial disease, leg-length
differences, and loss of vascular access in those children
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requiring repeated cardiac catheterizations; thus, optimal
antithrombotic treatment is extremely important to restore
arterial patency and avoid long-term sequelae.
Little information is available on the optimal treatment
of peripheral arterial thrombosis in children, and treatment
guidelines are usually extrapolated from recommendations
in adults [4]. This approach is not optimal for a several
reasons. Firstly, the etiology of arterial thrombosis in chil-
dren differs substantially from that of adults. In children,
arterial thrombosis usually occurs after arterial catheter-
ization procedures in otherwise normal vessels, reflecting
a direct “cause-and-effect” relationship between risk factor
and thrombotic event [3]. In contrast, the cause-and-effect
relationship in adults is more indirect with risk factors that
include hyperlipidemia, diabetes, hypertension, smoking,
and obesity, which cause vascular occlusion by accelerat-
ing atherosclerosis [5]. Secondly, both the coagulation and
fibrinolytic systems in children differ significantly from
adults. Hemostatic differences likely affect not only the use
of, but also the response to, anticoagulant and thrombolytic
agents in children compared with adults [6, 7]. Thirdly, risk
factors for bleeding complications during anticoagulant or
thrombolytic therapy are age dependent, with neonates and
infants being particularly at increased risk.
Current recommendations for the treatment of catheter-
related arterial thrombosis in infants and children include
the administration of therapeutic doses of intravenous
heparin [4]. Information on the optimal duration of
heparin therapy is not available. Unlike the frequent use
in adults, thrombolytic therapy in children is usually only
recommended for extensive arterial thrombosis causing
threatened limb or organ viability [4]. The limited and
cautious use of thrombolysis in children derives from
data showing that thrombolytic therapy is associated with
a weak benefit and a significant increased risk of bleeding,
particularly in newborns and infants [8].
Low molecular weight heparin (LMWH) has important
advantages over unfractionated heparin (UFH), including
predictable pharmacokinetics, subcutaneous administra-
tion, minimal monitoring, and fewer adverse effects [9].
While recent studies have provided important information
on the use of LMWH in children with venous thrombosis,
little information is available on the use of this drug in the
treatment of arterial thrombosis in the young [10, 11].
This study aims to investigate dose requirements, effi-
cacy, and safety of enoxaparin for the treatment of catheter-
related arterial thrombosis in newborns and infants with
CHD.
Methods
Patient population
Infants aged 0–12 months with CHD, who received
therapeutic doses of enoxaparin for the treatment of
catheter-related arterial thrombosis at the University
Children’s Hospital of Zurich from January 2002 to
December 2005, represent the cohort of this study. All
included infants had clinical suspicion of arterial throm-
bosis confirmed by objective radiological tests including
Doppler ultrasonography and/or angiography, and Doppler
ultrasound examination on follow-up. Data concerning
age at the time of thrombosis, weight, gender, type of
cardiac catheter and duration of cardiac catheteriza-
tion, hematocrit at the time of thrombosis, dosing of
enoxaparin (initial dose, dose required to achieve target
anti-factor (F) Xa and maintenance dose), anti-FXa
levels, duration of therapy, resolution of thrombosis,
and bleeding complications during enoxaparin therapy
were collected in all infants from clinical, laboratory,
and radiological records. Our practice regarding prophy-
lactic anticoagulation during cardiac catheterization is
to administer UFH at bolus doses of 100 and 50 U/kg
in the first and second hours, respectively, followed by
subsequent doses depending on the activated clotting
time. This study conformed to the declaration of Helsinki,
and was approved by the Research Ethics Boards of
the University Children’s Hospital of Zurich (Zurich,
Switzerland).
Treatment with enoxaparin
Dosing and monitoring of enoxaparin therapy were
performed following guidelines established by the hema-
tology service at our institution in accordance to the
“Sixth ACCP Consensus Conference on Antithrombotic
Therapy” [12]. Enoxaparin was administered through
a subcutaneous catheter (Insuflon, Unomedical A/S,
Roskilde, Denmark) at a dose of 1.5 mg/kg every 12 h in
infants aged 0–2 months, and 1 mg/kg every 12 h in infants
aged 2–12 months. Doses of enoxaparin were considered
therapeutic when anti-FXa levels of 0.5–1.0 U/ml were
achieved in blood samples taken 4 h following a second
or third subcutaneous injection. Dose adjustments and
subsequent anti-FXa measurements were performed
according to a validated nomogram [12].
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Characteristics Infants < 1 month Infants 2–12 months
(n = 21) (n = 11)
Gender
Male 13 7
Female 8 4
Age at the time of thrombosis
Mean 10 days 3.6 months
Median 7 days 3.1 months
Congenital heart disease
Non-cyanotic
Atrial and/or ventricular septal defect 1 4
Coarctation of the aorta 2 1
Aortic stenosis 2 1
Anomalies of the aortic arch 3 0
Bland–White–Garland syndrome 0 1
Cyanotic
Tetralogy of Fallot 1 1
Pulmonary/tricuspidal atresia 1 0
Transposition of the great arteries 6 1
Anomalous pulmonary venous return 1 0
Hypoplastic left heart syndrome 2 1
Single ventricle 2 1
Arterial catheter
Umbilical 1 0
Femoral 12 4
Cardiac 8 7
Location of thrombosis
Aorta 1 0
Iliac arterya 11 3
Femoral arterya 14 8
a Five infants < 1 month of age developed thrombosis in both the iliac and femoral arteries
Table 1 Demographic and
clinical characteristics of
newborns and infants
Variable Infants < 1 month Infants 2–12 months
Initial dose (mg/kg per dose)
Mean (95% CI) 1.48 (1.34-1.62) 1.12 (0.96-1.28)
Median 1.50a 1.04a
Range 0.74–1.98 0.88–1.70
Dose to achieve target anti-FXa (mg/kg per dose)
Mean (95% CI) 1.62 (1.45-1.78) 1.12 (0.95-1.28)
Median 1.61b 1.04b
Range 0.74–2.47 0.86–1.70
Maintenance dose (mg/kg per dose)
Mean (95% CI) 1.59 (1.39-1.80) 1.12 (0.96-1.28)
Median 1.69c 1.04c
Range 0.65–2.47 0.88–1.70
The p-values indicate significant differences in median dose requirements between infants under
1 month of age and infants between 2 and 12 months of age: ap = 0.002; bp = 0.0002; cp = 0.001
Table 2 Dose requirements of
enoxaparin. F-factor;
CI confidence interval
Due to the lack of evidence-based recommendations
regarding the optimal duration of therapy, the practice at
our institution was to treat catheter-related arterial throm-
bosis with LMWH from the time of diagnosis until clinical
and radiological resolution of thrombosis occurred, and for
a maximal duration of 3–4 weeks. In infants with persistent
thrombosis on ultrasonographic follow-up after this period
of time, heparin therapy was changed to anti-platelet ther-
apy with aspirin for 3–6 months. Depending on the clinical
conditions of the infants, therapy with enoxaparin was per-
formed in the hospital or at home.
Outcome
Efficacy of enoxaparin therapy was determined by reso-
lution or extension of the arterial thrombus using Doppler
ultrasonography performed by three experienced pediatric
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radiologists trained in Doppler ultrasonography. Reso-
lution of arterial thrombus was defined as complete if
the thrombus was no longer detected and/or the blood
flow had returned to normal, as partial if only a reduction
of the thrombus and/or a still reduced blood flow was
detected, and as no resolution when no changes in size or
volume of the thrombus and/or no changes in blood flow
were observed. Once radiological resolution occurred, no
attempt was made to perform radiological follow-up in the
absence of clinical signs of recurrence. In infants showing
partial or no resolution, Doppler ultrasonography was
performed at regular bases, usually during cardiological
follow-up for ≥ 3 months.
Safety of enoxaparin therapy was determined by major
and minor bleeding associated with treatment. Major
bleeding included hemorrhage into internal organ sites,
in the retroperitoneum, in the central nervous system,
or a hemorrhage of any source requiring blood-product
transfusion. Minor bleeding included mucosal bleeding
and bleeding from vascular puncture sites.
Laboratory methods
Blood samples for the determination of anti-FXa were
drawn from peripheral veins 4 h following a subcutaneous
injection. Blood samples were collected into tubes con-
taining 0.106 mol/l trisodium citrate solution (1.4 ml final
volume). The volume of trisodium citrate was adjusted
when hematocrit values were > 0.55. Anti-FXa was meas-
ured by a chromogenic assay (STA Rotachrom Heparin,
Roche Diagnostics, Rotkreuz, Switzerland). For calibra-
tion, STA-Calibrator HBPM/LMWH kits (Diagnostica
Stago, Asnieres, France) were used.
Statistical analysis
Data are described as means, medians, with ranges and
95% confidence intervals (CI) as appropriate. Statistical
significant differences between groups were calculated by
using the Mann–Whitney U-test. To assess for relations
between different variables (age, type of CHD, hematocrit,
initial anti-FXa, time gap between diagnosis of thrombosis
and initiation of enoxaparin therapy, type of arterial
catheter, duration of cardiac catheterization, and type of
cardiac catheterization) and resolution of thrombosis, the
Fisher’s exact test was used. Differences with p-values
≤ 0.05 were considered significant. Analysis was per-
formed using GraphPad InStat for Windows (GraphPad
Software, version 3.05, San Diego, Calif.).
Results
Patient population
A total of 56 newborns and infants with CHD were diag-
nosed with catheter-related arterial thrombosis. Of these
56 patients, 24 (43%) had to be excluded from the present
analysis. Reasons for exclusion were no treatment with
enoxaparin due to renal insufficiency (n = 2), treatment
with UFH in infants with unstable clinical conditions
possibly requiring rapid on/off anticoagulation (n = 7),
treatment with dalteparin (n = 1), treatment with aspirin
only (n = 3), no confirmation of arterial thrombosis by
radiological tests (n = 8), loss to follow-up (n = 2), and no
parental consent to access patient records for study pur-
poses (n = 1). The remaining 32 (57%) patients constitute
the cohort for this analysis.
Demographic and clinical characteristics of patients are
depicted in Table 1. Of the 32 patients, 21 were newborns,
and 11 were between 2 and 12 months of age at the time
of arterial thrombosis. The mean gestational age and birth
weight of newborns were 38.6 weeks (median 39.2 weeks,
range 33.3–41.1 weeks) and 3034 g (median 3020 g, range
2020–4130 g), respectively. Arterial thrombosis occurred
at a mean of 3.8 days (median 2 days, 95% CI 1.19–6.57)
following the placement of an indwelling arterial catheter,
and 0.8 days (median 1 day, 95% CI 0.27–1.32) following
cardiac catheterization (p = 0.01). From the 15 cardiac
catheterization procedures, 8 were diagnostic and 7 were
interventional. Cardiac catheterization was performed
using a 4-F sheath for vascular access in 14 infants, and
a 6-F sheath in 1 infant. Clinical signs of catheter-related
thrombosis included the presence of a cool and pale
extremity in 15 infants (47%), loss of a palpable arterial
pulse in 29 infants (90%), and decreased blood pressure
measured by Doppler in 12 infants (37.5%). None of the
infants presented severe life-threatening limb viability.
Treatment with enoxaparin
Overall, enoxaparin therapy was started at a mean of
1.9 days (median 0.5 day, 95% CI 0.85–2.96) following
diagnosis of arterial thrombosis. Initiation of enoxaparin
therapy was significantly delayed in infants less than
1 month of age (mean 2.66 days, median 1 day, 95% CI
1.18–4.14) as compared with infants aged 2–12 months
(mean 0.45 days, median 0 day, 95% CI –0.46–1.37;
p = 0.02).
Dose requirements of enoxaparin in both infants less
than 1 month of age and infants aged 2–12 months are
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presented in Table 2. Median initial dose, median dose to
achieve target anti-FXa, and median maintenance dose
were significantly higher in infants less than 1 month of
age as compared with infants aged 2–12 months. Although
not statistically significant, a trend of increased dose re-
quirements to achieve and maintain anti-FXa as compared
with initial dose requirements was observed in infants less
than 1 month of age (Table 2). Mean anti-FXa level within
the target range was 0.65 U/ml (median 0.57 U/ml, 95% CI
0.55–0.75 U/ml) in infants less than 1 month of age, and
0.64 U/ml (median 0.57 U/ml, 95% CI 0.52–0.75 U/ml) in
infants aged 2–12 months.
Median duration of enoxaparin therapy was 12 days
(range 3–93 days, 95% CI 10.03–27.01) in infants less than
1 month of age, and 16 days (range 4–91 days; 95% CI
9.10–51.44) in infants aged 2–12 months (p = 0.51).
In three infants, enoxaparin therapy was continued for
3 months due to the presence of a concomitant venous
thrombosis. Following discontinuation of enoxaparin
therapy, a total of 17 (53%) infants received anti-platelet
therapy with aspirin, and 2 infants (6%) oral anticoagu-
lation with phenprocoumon. Indications for aspirin ther-
apy included arterial thrombosis and conditions related
to the congenital heart disease in 8 (47%) and 9 (53%),
respectively, of the 17 infants. Indications for oral anti-
coagulation were related to the congenital heart disease in
both cases.
Outcome
Overall, complete resolution of arterial thrombosis oc-
curred in 29 (91%) of all 32 patients, including 20 (95%)
of the 21 infants less than 1 month of age and 9 (82%)
of the 11 infants aged 2–12 months. Complete resolution
was observed on follow-up Doppler ultrasonography at
a mean of 27 days (median 12.5 days, range 5–187 days,
95% CI 7.1–46.8) in infants less than 1 month of age,
and 13.5 days (median 12 days, range 2–28 days, 95% CI
46.3–20.7) in infants aged 2–12 months after initiation of
enoxaparin therapy (p = 0.47). Partial and no resolution of
arterial thrombosis was observed in 1 (3%) and 2 (6%) of
the 32 patients, respectively, at a mean follow-up time of
4.3 months after initiation of enoxaparin therapy. Age at
the time of thrombosis, type of congenital heart disease,
hematocrit, initial anti-FXa, time gap between diagnosis
of thrombosis and initiation of enoxaparin therapy, type
of arterial catheter, duration of cardiac catheterization,
and type of cardiac catheterization were not related to
resolution of arterial thrombosis.
Major bleeding complications occurred in 1 (3%) of the
32 infants. This 6-day-old boy presenting catheter-related
arterial thrombosis following cardiopulmonary bypass for
the repair of an interrupted aortic arch developed hemor-
rhagic pericardial effusion 2 days after initiation of enoxa-
parin therapy. The infant required cardiopulmonary resus-
citation and surgery with the placement of a pericardial
drainage due to cardiac tamponade. At the time of bleed-
ing, the dose of enoxaparin was 1.5 mg/kg per dose, and
the anti-FXa was 0.62 U/ml. No relevant minor bleeding
complications were observed. No clinical signs of recur-
rence during the follow-up time were observed.
Discussion
Although catheter-related arterial thrombosis are well-
known complications of indwelling arterial catheters or
cardiac catheterization procedures in infants with CHD,
limited information is available on the optimal treatment
of these thrombotic complications. The present study is
by far one of the largest cohort studies evaluating the
use of enoxaparin in the treatment of catheter-related
arterial thrombosis in infants with CHD. Results of this
study demonstrate that enoxaparin represents an efficient
and safe anticoagulation therapy for non-life-threatening
catheter-related arterial thrombosis in these infants. Rec-
ommendations from the ACCP Consensus Conference
on Antithrombotic Therapy for the treatment of femoral
artery thrombosis following cardiac catheterization and
peripheral arterial catheter-related thrombosis in children
include therapeutic doses of intravenous UFH with or
without thrombolysis, depending on the clinical situ-
ation [4, 12]. Since 2002 enoxaparin has been increasingly
used at our institution for two major reasons. The first is
that LMWH has important pharmacokinetic advantages
and a more convenient clinical use compared with UFH.
Minimal monitoring and subcutaneous administration
are only two of the important benefits that spare the use
of central venous lines in children with poor venous
access, and possibly decrease the risk of central venous
line-related thrombosis, which is known to occur at a high
incidence in children with CHD; the second is the inferior
outcome observed in a retrospective evaluation of infants
with CHD treated with UFH and/or thrombolysis for
non-life-threatening catheter-related arterial thrombosis
at our institution between 1997 and 2001 [2]. In this
study, complete and partial/no resolution was noted in 70
and 30% of cases, respectively. Bleeding complications
occurred in 2% of patients treated with UFH and in 54%
of patients receiving thrombolysis [2].
In the present study, complete resolution of arterial
thrombosis occurred in 91% of all infants at a mean
of 23 days following initiation of enoxaparin therapy,
whereas bleeding complications occurred in only 3%.
As compared with studies on infants with predominantly
venous thrombosis, enoxaparin in our cohort was more
effective and associated with a comparable low risk of
bleeding complications [13, 14]. No studies on infants
with exclusively arterial thrombosis treated with LMWH
are available for comparison. It is evident, however, that
compared with our retrospective data, the introduction of
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enoxaparin at our institution has provided a rapid, more
efficient, and safer alternative to UFH or thrombolysis for
the treatment of non-life-threatening catheter-related arter-
ial thrombosis [2]. The increased efficacy of enoxaparin
compared with UFH and thrombolysis is possibly related
to the composition of arterial thrombi, which develop in
high flow conditions and are composed mainly of platelet
aggregates bound together by thin fibrin strands [15].
Increasing evidence suggests that the anticoagulant ef-
fect of UFH is impaired by platelets to a greater extent
than LMWH, and that platelet interaction is much more
inhibited by LMWH than UFH [16–18]. In addition,
animal models have shown that platelet-rich thrombi are
particularly resistant to thrombolysis, and that platelets
and fibrin still accumulate on lysing thrombi during
effective thrombolytic therapy [19].
Previous studies in infants and children have demon-
strated that doses of enoxaparin to achieve adult therapeu-
tic anti-FXa levels of 0.5–1.0 U/m are age dependent, with
preterms and newborns having increased requirements
compared with older infants and children [12–14, 20–23].
Possible explanations for the increased requirements of
LMWH in newborns include a faster clearance of LMWH
due to a larger volume of distribution, and decreased
plasma concentrations of antithrombin in newborns com-
pared with older children [10]. While confirming these
findings, a trend of increased dose requirements to achieve
target anti-FXa as compared with published initial dose
recommendations was observed in our infants less than
1 month of age. Of particular interest was the finding
that anti-FXa levels remained close to the lower limit of
the target range despite increased doses of enoxaparin
in most of the cases. This finding, together with the
high resolution rate, raises the question of whether the
therapeutic anti-FXa range will be lower than that for
adults.
Forty-three percent of infants who developed catheter-
related arterial thrombosis were not included in this
study mostly due to no treatment with enoxaparin, and
the lack of radiological confirmation of thrombosis.
Catheter-related arterial thrombosis usually occurs in
critically ill infants with serious underlying diseases.
When CHD is concerned, these infants usually require
intensive care following cardiopulmonary bypass or
cardiac catheterization, are often in hemodynamically
unstable conditions, possibly require urgent re-operation,
or develop complications such as renal insufficiency. Due
to the longer half-life of LMWH and the fact that LMWH
are cleared principally by the renal route, treatment of
arterial thrombosis with UFH instead of enoxaparin is
preferable in these infants. While allowing a bedside,
non-invasive examination compared with contrast angiog-
raphy, which is considered the gold standard, Doppler
ultrasound in small infants is not always feasible, and
radiological diagnosis of thrombosis becomes a major
issue; thus, several infants with typical clinical signs of
arterial thrombosis treated with enoxaparin had not been
included in this study due to the lack of confirmation of
thrombosis by Doppler ultrasound.
Conclusion
In conclusion, results of this study show that enoxaparin is
an efficient and safe form of anticoagulation for newborns
and infants with CHD and non-life-threatening catheter-
related arterial thrombosis, possibly representing a valid
alternative to the currently recommended intravenous
UFH. Multicenter randomized clinical trials are required
to properly define efficacy and safety of LMWH over UFH
for the treatment of catheter-related arterial thrombosis in
children. Further studies are also required to determine
pediatric anti-FXa therapeutic range and optimal duration
of enoxaparin therapy for catheter-related arterial throm-
bosis in children, as well as to assess the long-term benefit
of the use of enoxaparin in the studied population.
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